

PubMed

U.S. National Library of Medicine
National Institutes of Health



Display Settings: Abstract

J Neurol. 2006 Sep;253 Suppl 5:V64-5.

Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).

Pongratz D.

Friedrich-Baur-Institut, Medizinischen Fakultät, Neurologischen Klinik und Poliklinik, Ludwig Maximilians Universität München, Ziemssenstrasse 1, 80336, München, Germany. dieter.pongratz@fbs.med.uni-muenchen.de

Erratum in:

J Neurol. 2008 Feb;255(2):308.

Polymyositis, dermatomyositis, and inclusion body myositis are idiopathic inflammatory myopathies of unknown etiology with autoimmune pathogenesis. For choosing an individual and efficient therapy, diagnostic assignment is an important factor. Therapeutic options in dermatomyositis and polymyositis include corticosteroids and immunosuppressives. Intravenous immunoglobulins are only needed in special cases. In inclusion body myositis, corticosteroids and immunosuppressives are not successful. At the moment intravenous immunoglobulins are the only therapeutic possibility.

PMID: 16998756 [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

LinkOut - more resources

You are here: [NCBI](#) > [Literature](#) > PubMed

[Write to the Help Desk](#)